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Abstract
Background: We determined whether it is feasible to identify important changes in care management resulting
from cardiovascular magnetic resonance (CMR) in patients who activate the primary percutaneous coronary
intervention (PPCI) pathway from hospital episode data, in order to construct a composite primary outcome
(hypothesised to reduce the risk of major adverse cardiac-related events, MACE) to compare patients exposed to
CMR or not.
Methods: We used Hospital Episode Statistics (HES) and Patient Episode Database for Wales (PEDW) to identify
clinical events that reflected important changes in management in the year following the index admission in five
subgroups of patients who activated the PPCI pathway recruited as part of a feasibility cohort study (n = 1655 with
HES/PEDW data). For all subgroups, we identified frequency of events and time to the first event for each change
in management.
Results: We identified all clinical events (new diagnoses, additional diagnostic tests and procedures) except for
medication prescriptions. Diagnostic tests were underestimated because most are carried out in outpatient clinics
and outpatient datasets had missing procedure codes for 74% of patients (some tests done in hospital may also
not be recorded). We successfully tabulated frequencies of events and distributions of times to first event for most
changes in management by CMR status and in CMR / non CMR centres.
Conclusions: It is feasible to identify changes in care management between patients who have / do not have CMR
within relevant patient subgroups. Further work to derive a weighting algorithm is required before attempting to
combine the events in a composite endpoint.
Keywords: Cardiovascular magnetic resonance (CMR), Primary percutaneous coronary intervention (PPCI), Hospital
Episode Statistics (HES), England, Patient episode database Wales (PEDW)
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Background
Prospective patient registries provide a real-world view
of clinical practice and patient outcomes including safety
(http://www-new.njrcentre.org.uk/njrcentre/Home/
tabid/36/Default.aspx) [1–4]. They can also be useful to
estimate comparative effectiveness providing that they
can accrue sufficient data quickly enough to estimate
treatment effects with adequate precision. In patients
who have attended an Emergency Department (ED) with
ST-elevation myocardial infarction (STEMI), the fre-
quency of subsequent major adverse cardiac-related
events (MACE) has decreased markedly over the past
20 years [5–8]. This decrease has been achieved mainly
through improvements in management and use of
evidence-based pharmacological and interventional ther-
apies. Therefore, studies evaluating the effectiveness of
alternative management pathways in STEMI populations
using MACE as the primary outcome require large sam-
ple sizes to achieve satisfactory power.
We conducted a study to determine the feasibility of
setting up a registry linking data collected during
usual care to assess the clinical and cost-effectiveness
of cardiovascular magnetic resonance (CMR) in pa-
tients who activate the primary percutaneous coronary
intervention (PPCI) pathway [9]. Although a long-
term objective of the registry would be to compare the
incidence of MACE in patients who do or do not have
CMR after the index event, the relatively low fre-
quency of MACE after PPCI in this population (about
13% [9]) means that the study would have to accrue
over 27,000 subjects to detect a clinically important
(assumed to be 10%) relative reduction in the inci-
dence of MACE with 90% power. Therefore, a key ob-
jective of the feasibility study was to define a primary
composite outcome, acceptable to cardiologists and
other stakeholders (e.g. healthcare providers) as repre-
senting a clinically important change in management
(e.g. expected to prevent future MACE and change
practice/commissioning) resulting from CMR that
could be used for the registry in the medium term.
We identified important changes in management
resulting from CMR (and the specific patient subgroups
these changes in management relate to) using formal
consensus methods [10]. In this paper, we report on
whether it is feasible to identify these changes in man-
agement during follow up from routinely collected hos-
pital episode data (Hospital Episode Statistics, HES;
Patient Episode Database Wales, PEDW). HES is com-
monly used for outcome ascertainment in cardiovascular
disease populations and has been shown to be valid and
reliable in both registries and clinical trials [11–14]. If
successful, this process of ascertainment could be used
to define a primary composite outcome to compare
groups of PPCI patients exposed to CMR or not.
Methods
Patient recruitment for the feasibility study
Patients were recruited from four NHS hospitals in
England and Wales with 24/7 PPCI services (Bristol,
Leeds, Swansea and Cardiff ) between May 2013 and
September 2014. Two hospitals (Bristol and Leeds)
were defined as “CMR centres”, i.e. hospitals that had a
local dedicated CMR service; the other two (Swansea
and Cardiff ) were defined as “non-CMR centres”, i.e.
hospitals without access to a local dedicated CMR ser-
vice. Patient identification, recruitment and consent
have been described previously [9]. Patients entered the
cohort at the point they activated the PPCI pathway
(i.e. had an emergency angiogram), regardless of
whether PPCI was carried out or not.
Formal consensus to identify important changes in
management (and the subgroups of patients to which
these referred)
We used formal consensus (literature review and cardi-
ologist expert opinion) to formulate consensus state-
ments about important changes in management arising
from the use of CMR in patients who activate the PPCI
pathway. The formal consensus process has been de-
scribed elsewhere [10]. Five patient subgroups were
identified as potentially benefitting from CMR, namely
patients who: i) have an out of hospital cardiac arrest
(OHCA); ii) have “normal” (unobstructed) coronary ar-
teries; iii) develop LV thrombus after STEMI; iv) have
multivessel disease (MVD, defined as 2 or more vessels
with > 50% stenosis pre-PCI); and v) underwent PPCI
and have a suspected poor prognosis (assumed to be
identifiable from CMR imaging biomarkers).
Identifying the patient subgroups defined through formal
consensus
Three of the patient subgroups (patients who underwent
PPCI, patients with unobstructed coronary arteries and
patients with MVD) were defined using data collected at
cohort entry (related to the index admission). Two sub-
groups, patients who had had an OHCA and those who
went on to develop LV thrombus, could only be identi-
fied from HES / PEDW (data collected at cohort entry
relating to the presence or absence of these conditions
were missing for a large proportion of participants),
using ICD-10 diagnosis codes I46 “Cardiac arrest” and
I23.6 “Thrombosis of atrium, auricular appendage and
ventricle as current complications following acute myo-
cardial infarction”, respectively.
Identifying CMR exposure
CMR exposure was defined as documentation of CMR
in the imaging dataset (collected from “CMR centres”)
within 10 weeks of their index admission; this time
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frame was chosen to capture both urgent and non-
urgent (out-patient) CMR scans.
Identifying the key clinical “events” that reflected the
important changes in management
Initially, cardiologist members of the clinical team identi-
fied the key clinical “events” that they expected to reflect
the important changes in management characterised
through the consensus process. We then used HES and
PEDW inpatient and outpatient data to ascertain these
changes in management, compiling a list of diagnosis and
procedure codes (International Classification of Disease,
ICD-10; Office of Population Censuses and Surveys Classi-
fication of Interventions and Procedures, OPCS) represent-
ing the key clinical events with the help of a clinical coder.
Most changes in management were defined by Boolean
combinations of multiple ICD-10 / OPCS codes; for
example, the “use of additional diagnostic tests during
follow-up” was ascertained by OPCS codes for echocardi-
ography (K58.5 OR U20.1 OR U20.2 OR U20.3 OR U20.4
OR U20.5), single photon emission computed tomography
(SPECT) (U21.4); positron emission tomography (PET;
U10.4 OR U21.3 OR U36.2), intra vascular ultrasound
(IVUS; K51.2 OR L726), pressure-wire (K63.4 OR K63.5
OR K63.6) AND K51.8 AND Y44.2 AND Y53), radio-
nuclide angiocardiography (U10.5) or computed tomog-
raphy angiography (U10.2). We identified the key clinical
events relating to the changes in management for each pa-
tient subgroup separately. The full code list used to identify
changes in management is shown in the Additional file 1.
For those patients who underwent CMR, any outpatient
appointments that occurred between the index admission
and the date of CMR were excluded. We did not use Acci-
dent and Emergency (A&E) data because most of the
changes in management identified in the formal consensus
process were deemed unlikely to have occurred in the
A&E setting and diagnoses and procedures are not well
coded in the A&E dataset.
Statistical analysis
Data were analysed using Stata/IC (V13, StataCorp LP,
Texas, USA). The analysis was descriptive, with quanti-
tative results expressed as counts and percentages. We
calculated the frequencies of all events representing
changes in management (e.g. number of new diagnoses,
additional diagnostic tests, number / rate of outpatient
appointments, etc.) in patients who did / did not receive
CMR for each patient subgroup in the 12 months follow-
ing the index admission.
We also calculated the time to first event (in partici-
pants in whom an event occurred) for each change in
management (e.g. time to first new diagnosis, time to
the first diagnostic test, time to next revascularisation in
patients with multivessel disease, etc.) and summarised
these with medians and interquartile ranges (IQR). Dates
of events were available for all events, which allowed us
to describe the time to first event for each change in
management and for all subgroups, and to visualise the
data using Kaplan Meier curves and other time to event
plots. We did not compare differences between patients
who did / did not receive CMR in any of the subgroups
because this was not an objective; we were primarily in-
terested in the feasibility of identifying relevant events
and the frequencies of events in most subgroups were
small. We did not attempt to derive a composite out-
come because further research would be required to de-
rive an appropriate weighting algorithm to combine the
different clinical events.
Results
We recruited 1670 patients across the four hospitals, of
whom 1655 (99%) had HES/PEDW data. Of these, 89%
of patients underwent PPCI; 11% were found to have
unobstructed coronary arteries, 44% of patients had
MVD, 7% had out-of-hospital cardiac arrest (OHCA)
and 0.06% had left ventricular (LV) thrombus. The pro-
portions of patients in each subgroup were similar be-
tween hospitals, except for patients with MVD (19% in
hospital D vs. 48, 51 and 53% in hospitals A, B and C,
respectively) (Table 1).
Identifying changes in management in hospital episode
statistics data
The ICD-10 diagnosis codes and OPCS procedure codes
of the clinical events representing important changes in
management resulting from CMR are shown in Table 2.
We successfully identified the events described in the
table, except for medications; these are not available in
HES/PEDW data. We were also unable to obtain data
about medications on discharge for a large proportion of
the cohort. Therefore, we could not identify changes in
medication prescribed during follow up. All relevant
non-ischaemic diagnoses were identifiable in admitted
patient care data, as were procedures such as implant-
ation of devices, repeat revascularisation and additional
diagnostic tests. In contrast, we could not identify any of
these from outpatient care data because ICD-10 diagno-
sis codes and OPCS procedure codes associated with
each outpatient episode were missing for a large propor-
tion of patients. All outpatient visits should have a diag-
nostic code associated with the visit. However, for at
least one of their visits, 25% of patients had missing
ICD-10 diagnosis codes, 74% of patients had missing
OPCS procedure codes (which may indicate either that
no procedure took place or that a procedure took place
but was not recorded), and 74% of patients had un-
known “Unknown and unspecified causes of morbidity”
as their ICD-10 diagnosis code).
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Important changes in management by CMR status and in
CMR / non CMR centres
Tables 3 and 4 show the number of events and time to
first event representing changes in management in the
relevant patient subgroups identified in HES / PEDW up
to 12months after the index admission by CMR status
and in CMR vs non CMR centres, respectively. It was
possible to observe differences in both the frequency of
events and time to first event by CMR status or in CMR
vs non CMR centres. For example, across all subgroups,
patients in CMR centres had more outpatient appoint-
ments and an earlier time to first appointment (see Fig. 1
Table 1 Frequency of patient subgroups by hospital
Hospital A
(n = 758)
Hospital B
(n = 272)
Hospital C
(n = 316)
Hospital D
(n = 309)
Total
(n = 1655)
PPCI 651 (86%) 246 (90%) 291 (92%) 279 (90%) 1467 (89%)
MVD 361 (48%) 138 (51%) 169 (53%) 58 (19%) 726 (44%)
LV thrombus after PPCI 1 (0.13%) 0 0 0 1 (0.06%)
Unobstructed coronary arteries 107 (14%) 26 (10%) 25 (8%) 30 (10%) 188 (11%)
OHCA 57 (8%) 22 (8%) 16 (5%) 14 (5%) 109 (7%)
Percentages do not add up to 100 because some patients were in more than one subgroup
LV left ventricular, MVD multivessel disease, OHCA out of hospital cardiac arrest, PPCI primary percutaneous coronary intervention
Table 2 Data sources and definitions used for identifying changes in management up to 12 months after the index admission
Important change in
management resulting
from CMRa
Patient
subgroup
Data source ICD-10 diagnosis codes and OPCS procedure codes (up to 12 months
after the index admission)
New diagnosis (non-
ischaemic)
Unobstructed
coronary
arteries
OHCA
HES / PEDW admitted
patient care data
Any record of the following:
− Takotsubo cardiomyopathy (I42.8 AND F43.8)
− Myocarditis (I51.4)
− Pericarditis (I30 OR I31.0 OR I31.1 OR I31.9 OR I32.0 OR I32.1 OR
I32.8 OR I01.0 OR I02.0 OR I09.2)
− Endocarditis (I33.9)
− Coronary spasm (I20.1)
Changes in medication PPCI
MVD
LV thrombus after PPCI
Unobstructed coronary
arteries
OHCA
Not available Not available
Additional
diagnostic tests
PPCI
MVD
LV thrombus after PPCI
Unobstructed coronary
arteries
OHCA
HES / PEDW admitted
patient care data and
outpatient care data
Any record of the following:
− Echocardiography (K58.5 OR U20.1 OR U20.2 OR U20.3 OR U20.4 OR
U20.5)
− Single photon emission computed tomography (SPECT) (U21.4)
− Positron emission tomography (PET) scans (U10.4 OR U21.3 OR U36.2)
− Intravascular ultrasound (IVUS) (K51.2 OR L726)
− Pressure wire ((K63.4 OR K63.5 OR K63.6) AND K51.8 AND Y44.2 AND
Y53)
− Radionuclide angiocardiography (U10.5)
− Computed tomography angiography (U10.2)
Implantation
of devices
PPCI
OHCA
HES / PEDW admitted
patient care data
Any record of the following:
− Cardiac resynchronization therapy (CRT) (K60.7 OR K61.7 OR K59.6)
− Implantable cardioverter defibrillator (ICD) (K59 OR K72)
Revascularisation
(PCI or CABG)
within 3 months
MVD HES / PEDW admitted
patient care data
Any record of the following (up to 3 months after the index admission):
− PCI (K49 OR K50 OR K75)
− CABG (K40 OR K41 OR K42 OR K43 OR K44 OR K45 OR K46)
Frequency of
cardiology
outpatient
appointments
PPCI
MVD
LV thrombus after PPCI
Unobstructed coronary
arteries
OHCA
HES / PEDW
outpatient care data
Rate of outpatient visit attended (count of visits divided by follow-up time)
where the treatment speciality in which the consultant responsible was
working during the period of care was Cardiology (code = 320).
CMR cardiovascular magnetic resonance, HES Hospital Episode Statistics, ICD-10 International Classification of Diseases, LV left ventricular, OHCA out of hospital
cardiac arrest, MVD multivessel disease, OPCS Office of Population Census and Surveys Classification of Intervention and Procedures, PEDW Patient Episode
Database Wales, PPCI primary percutaneous coronary intervention
aIdentified in formal consensus
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for an example in the OHCA patient subgroup), and
more frequent diagnostic tests and implantation of de-
vices than patients in non CMR centres. Across most
patient subgroups, patients in CMR centres and patients
who had CMR seemed to have had an admission for an
additional diagnostic test later than patients in non-
CMR centres or patients who did not have CMR, re-
spectively (see Fig. 2 for an example of CMR vs no CMR
in the MVD patient group).
Discussion
Main findings
We have shown that it is feasible to identify clinical events
expected to prevent future MACE and describe their
frequencies and timing in relation to index PPCI pathway
activation using only routinely collected NHS hospital epi-
sode data. We were able to identify relevant patient sub-
groups specified previously by combining data about the
index event, which was obtained directly from hospitals,
with admitted patient care (APC) hospital episode data. For
each patient subgroup, we listed the “key clinical events”
(e.g. new diagnoses or procedures, additional diagnostic
tests, changes in medication, outpatient appointments) that
reflected a change in management, identified through dis-
cussions with relevant clinicians. By looking at care path-
ways, where available, we confirmed that we captured all
aspects of patient management in these key clinical events.
We then compiled a list of the relevant ICD-10 diagnosis
Table 3 Events and time to first event representing changes in management identified in HES / PEDW inpatient and outpatient
data up to 12 months after the index admission by CMR status
Number of events (%) identified in HES / PEDW up to 12months after the index admission and number of days (median and IQR) until
the first event after the index admission
Patient
subgroup
New diagnoses
(e.g. Takotsubo,
myocarditis,
pericarditis,
endocarditis,
coronary spasm)
Changes in
medication
Additional diagnostic
tests (ECHO, SPECT,
PET, IVUS, pressure-wire,
radionuclide angiocardiography,
CT angiography)
Implantation of
devices (CRT or ICD)
Revascularisation
(PCI or CABG)
within 3 months
Cardiology
outpatient
appointments
(median, IQR)
No. of
events
No. of
days
No. of events No. of days No. of
events
No. of
days
No. of
events
No. of
days
No. of
events
No. of
days
PPCI No data
available
N/A
CMR
(n = 152)
0 – 16 (11%) 107 (50, 240) 0 – 2 (1, 3) 64
(34, 99)
No CMR
(n = 1312)
10
(1%)
16 (8, 20) 129 (10%) 74 (27, 171) 6 (0.5%) 147
(48, 171)
1 (1, 2) 55
(33, 95)
MVD
CMR
(n = 104)
0 – 11 (11%) 85 (50, 221) 0 – 11 (11%) 99
(50, 180)
2 (1, 3) 76
(52, 116)
No CMR
(n = 622)
4 (1%) 13 (8, 110) 61 (10%) 62 (24, 130) 4 (1%) 147
(84, 169)
64 (10%) 66
(39, 122)
1 (1, 2) 57
(33, 95)
LV thrombus after PPCI N/A
CMR (n =
1)
0 – 0 – 0 – 3 (3, 3) 66
(66, 66)
No CMR
(n = 0)
0 – 0 – 0 – – –
Unobstructed coronary arteries
CMR (n =
35)
1 (3%) 358 (358,
358)
6 (17%) 93 (58, 140) 1 (3%) 78
(78, 78)
2 (1, 3) 67
(52, 121)
No CMR
(n = 139)
1 (1%) 180 (180,
180)
12 (9%) 123 (78, 284) 3 (2%) 245
(71, 262)
1 (0, 2) 67
(44, 106)
OHCA
CMR (n =
14)
0 – 2 (14%) 110 (79, 141) 0 – 1 (1, 3) 65
(61, 104)
No CMR
(n = 95)
1 (1%) 48 (48, 48) 10 (11%) 62 (48, 93) 5 (5%) 126
(71, 167)
1 (1, 2) 64
(41, 99)
CABG coronary artery bypass grafting, CMR cardiovascular magnetic resonance imaging, CRT cardiac resynchronisation therapy, ECHO echocardiography, HES
Hospital Episode Statistics, ICD implantable cardioverter defibrillator, IVUS intravascular ultrasound, IQR interquartile range, LV left ventricular, MVD multivessel
disease, OHCA out of hospital cardiac arrest, PET positron emission tomography, PCI percutaneous coronary intervention, PEDW Patient Episode Database Wales,
PPCI primary percutaneous coronary intervention
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codes and OPCS procedure codes, identified these codes in
hospital episode data for participants up to 12months fol-
lowing the index procedure, and tabulated the events by pa-
tient subgroup.
We considered both the frequency of the events repre-
senting important changes in management and time to
the first event for a composite primary outcome. This is
because, for some changes in management (e.g. add-
itional revascularisation for MVD patients or a new
diagnosis in patients with unobstructed coronary arter-
ies), it is the time to the event that represents the main
change in management resulting from CMR. For other
changes in management (e.g. additional diagnostic tests
in patients with unobstructed coronaries), it is a change
in the frequency/rate of an event this would represent
the main change in management (e.g. a patient receiving
fewer tests or outpatient appointments). We were able
to tabulate the frequencies of events and their timing,
and visualise these by CMR status (at the patient and
centre level) for all patient subgroups. We were able to
observe differences in the process of healthcare in all pa-
tient subgroups by CMR status. We did not explore pos-
sible reasons for apparent differences since this was not
the aim of our study; the feasibility of implementing the
consensus statements using hospital episode data was
our main objective.
Composite endpoints combine several events of inter-
est within a single outcome variable. A composite
Table 4 Events and time to first event representing changes in management identified in HES / PEDW inpatient and outpatient
data up to 12 months after the index admission in CMR vs. non CMR centres (hospitals A and B vs. hospitals C and D, respectively)
Number of events (%) identified in HES / PEDW up to 12months after the index admission and number of days (median
and IQR) until first event after the index admission
Patient subgroup New diagnoses
(e.g. Takotsubo,
myocarditis,
pericarditis,
endocarditis,
coronary spasm)
Changes in
medication
Additional diagnostic
tests (ECHO, SPECT,
PET, IVUS, pressure-wire,
radionuclide
angiocardiography,
CT angiography)
Implantation of
devices (CRT or ICD)
Revascularisation
(PCI or CABG)
within 3 months
Cardiology
outpatient
appointments
(median, IQR)
No. of
events
No. of
days
No. of
events
No. of
days
No. of
events
No. of
days
No. of
events
No. of
days
No. of
events
No. of
days
PPCI No data available N/A
CMR centres
(n = 897)
6 (1%) 14
(8, 17)
112 (12%) 79
(33, 205)
5 (1%) 167
(126, 171)
2 (1, 3) 46
(30, 81)
Non CMR centres
(n = 567)
4 (1%) 20
(14, 34)
33 (6%) 45
(24, 116)
1 (0.2%) 48
(48, 48)
1 (0, 1) 90
(57, 126)
MVD
CMR centres
(n = 499)
4 (1%) 13
(8, 110)
61 (12%) 69
(32, 159)
4 (1%) 147
(84, 169)
53 (11%) 71
(41, 151)
2 (1, 3) 52
(32, 87)
Non CMR centres
(n = 227)
0 – 11 (5%) 59
(15, 122)
0 – 22 (10%) 63
(43, 88)
1 (0, 1) 95
(68, 136)
LV thrombus after PPCI N/A
CMR centres (n = 1) 0 – 0 – 0 – 3 (3, 3) 66
(66, 66)
Non CMR centres
(n = 0)
– – – – – – – –
Unobstructed coronary arteries
CMR centres
(n = 133)
2 (2%) 269
(180, 358)
16 (12%) 103
(68, 205)
4 (3%) 162
(75, 254)
1 (0, 2) 65
(46, 103)
Non CMR centres
(n = 41)
0 – 2 (5%) 184
(69, 299)
0 – 0 (0, 1) 89
(54, 133)
OHCA
CMR centres
(n = 79)
0 – 9 (11%) 79
(62, 141)
4 (5%) 147
(99, 169)
2 (1,3) 63
(42, 95)
Non CMR centres
(n = 30)
1 (3%) 48
(48, 48)
3 (10%) 48
(5, 74)
1 (3%) 48
(48, 48)
1 (0,1) 86
(52, 105)
CABG coronary artery bypass grafting, CMR cardiovascular magnetic resonance imaging, CRT cardiac resynchronisation therapy, ECHO echocardiography, HES
Hospital Episode Statistics, ICD implantable cardioverter defibrillator, IVUS intravascular ultrasound, IQR interquartile range, LV left ventricular, MVD multivessel
disease, OHCA out of hospital cardiac arrest, PET positron emission tomography, PCI percutaneous coronary intervention, PEDW Patient Episode Database Wales,
PPCI primary percutaneous coronary intervention
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Fig. 1 Number of cardiology outpatient appointments up to 12months after the index event and time to each appointment for patients in the OHCA
subgroup by CMR vs non CMR centre
Fig. 2 Kaplan-Meier curve for time to first additional diagnostic test in the 12months after the index event for patients in the MVD subgroup by CMR status
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endpoint is intended to increase the frequency of a bin-
ary primary outcome and thereby increase the power of
a study for a given relative treatment effect (e.g. risk,
odds or hazard ratio). We did not attempt to combine
clinical events to derive a composite primary outcome,
either by subgroup or overall, mainly because we had no
basis on which to weight different events. The derivation
of a weighting algorithm to incorporate the “importance”
of different clinical events would require further re-
search, possibly involving a formal consensus process
with clinicians, commissioners and patients, in order to
provide a rationale for its use in a future registry asses-
sing the clinical effectiveness of CMR in patients who
activate the PPCI pathway. Another difficulty is that
clinical events were characterised by different metrics
(frequencies and rates) in our study, so some changes in
management (e.g. the rate of cardiology outpatient
appointments or additional diagnostic tests; changes in
medication) cannot easily be included in a composite
outcome for a time-to-event model.
Strengths and limitations
Our study has several strengths. It is based on important
changes in management and hospital activities previ-
ously identified systematically using formal consensus
methodology, with input from a range of all stakeholders
(clinicians, methodologists and HES coders). By using
routinely collected hospital data, the study benefits from
an efficient design and avoids the use of primary data
collection. Our decision to use HES/PEDW data rather
than local hospital systems was also based on the fact
that follow up data would not be available from local
hospital systems for patients who are repatriated to
other hospitals.
A major limitation is that we had no data on medica-
tions, either at hospital discharge or during follow up.
Medications prescribed at discharge should, in principle,
have been easy to obtain from participating hospitals;
however, none of the hospitals had electronic pharmacy
records that could be linked by a common patient iden-
tifier. Medications (either newly initiated or changes to
existing prescriptions) could not be obtained during fol-
low up because there are no medication records in any
of the hospital episode datasets. There was consensus
that initiation, withdrawal or changes in medication rep-
resented an important change in management for all our
patient subgroups [10], in particular patients with LV
thrombus for whom anticoagulation therapy is the main
change in management. This limitation should be over-
come in the near future with the increasing implementa-
tion and use of hospital electronic prescribing (EP)
systems [15]. A potential solution to the lack of medica-
tions data during follow up is linkage of data collected
from hospitals and hospital episode data with data from
the Clinical Practice Research Datalink (CPRD), a pri-
mary care dataset that has detailed information on medi-
cations (https://www.cprd.com/). Only a subset of GP
practices (6%) contribute data to CPRD, so medications
data would only be available for a proportion of patients
in a registry.
Other changes in management (e.g. additional diag-
nostic tests) were likely underestimated because a large
proportion of diagnostic tests are performed on an out-
patient basis, and some tests, such as bedside echocardi-
ography, are not recorded in the admitted patient care
dataset. Although we could identify the frequency of
outpatient appointments under the cardiology specialty
(and could have done so for cardiac surgery or any other
related specialty), we could not identify the tests them-
selves because test codes are not well recorded in out-
patient datasets.
Our approach to constructing a proxy outcome reflects
our original concept and appears to be feasible when the
important changes in management are hypothesised to
cause a change in the same direction in all events / activ-
ities included in a composite outcome for a subgroup.
However, through the consensus process [10], it became
apparent that some of the hypothesised changes in manage-
ment arising from CMR would not necessarily result in a
unidirectional change in the frequency or rate of an activity.
In several instances, an important change in management
was more appropriate targeting of a treatment activity to
the patients who were most likely to benefit, without neces-
sarily changing the overall frequency of the activity (poten-
tially constrained in publicly-funded health services). For
example, in patients with MVD, CMR may result in better
(i.e. more cost-effective) targeting of additional revasculari-
sation. In these situations, a simple evaluation of the fre-
quency or rate of a proxy outcome would not detect any
value of CMR to patients and the NHS. It is also worth not-
ing that some hospital activities representing the important
changes in management we identified (e.g. time to out-
patient appointments and additional diagnostic tests) will
be complicated by local NHS driven issues which may ob-
scure any CMR test related differences.
Although the “concept” of creating a composite out-
come reflecting changes in care management can be ap-
plied to any imaging technique for any disease
condition, our composite outcome was developed from
a consensus process with cardiologists which identified
the changes in management resulting from CMR rele-
vant to patients activating the PPCI pathway. The
outcome cannot therefore be applied to other imaging
techniques, even within the same population, since it re-
lies on CMR being able to identify specific complications
from the myocardial infarction (MI) that would not be
identifiable by other imaging techniques (at least not in
all relevant patient subgroups).
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Conclusions
We conclude that it is feasible to ascertain events
reflecting important changes in management, their fre-
quencies and times to first event from HES/PEDW data-
sets. One important changes in management (change in
medication) could not be identified from HES/PEDW
admission datasets or directly from hospitals; this limita-
tion should disappear as the NHS implements more
electronic systems. HES data are generally regarded as
reliable and have been used to identify most of the
events/activities we required [11–14]. Further work is re-
quired to validate the reliability of HES/PEDW codes for
identifying patient subgroups (OHCA and LV thrombus)
and the key events representing the important changes
in management (for example, by comparing with local
hospital data, where available) before use in a main
registry. Also, further work to derive a weighting algo-
rithm for each patient subgroup is required before
attempting to combine the events in a composite end-
point. Such an endpoint would need a careful assess-
ment of the effects on its single components and their
correlations, as the observed effect of the composite
does not necessarily reflect the effects of the single com-
ponents and will also require different weighting algo-
rithms for different patient subgroups.
Our composite primary outcome will not be used in a
large registry (as we had anticipated when we conceived
the study) because the registry itself has proved not to
be feasible at present due to limitations on data availabil-
ity (e.g. exposure to tests) and consent (e.g. conventional
ways of obtaining consent are too time consuming for a
registry with no primary data collection [9]). However,
this does not invalidate the concept of creating a com-
posite outcome that reflects changes in management as
a result of having an imaging test.
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